Multiple drug resistance protein (MDR-1), multidrug resistance related protein (MRP) and lung resistance protein (LRP) gene expression in childhood acute lymphoblastic leukemia
Keywords:
Drug resistance, Cancer, Children, Leukemia, Acute lymphocytic leukemia, GenesAbstract
CONTEXT: Despite the advances in the cure rate for acute lymphoblastic leukemia, approximately 25% of affected children suffer relapses. Expression of genes for the multiple drug resistance protein (MDR-1), multidrug resistance-related protein (MRP), and lung resistance protein (LRP) may confer the phenotype of resistance to the treatment of neoplasias. OBJECTIVE: To analyze the expression of the MDR-1, MRP and LRP genes in children with a diagnosis of acute lymphoblastic leukemia via the semiquantitative reverse transcription polymerase chain reaction (RT-PCR), and to determine the correlation between expression and event-free survival and clinical and laboratory variables. DESIGN: A retrospective clinical study. SETTING: Laboratory of Pediatric Oncology, Department of Pediatrics, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Brazil. METHODS: Bone marrow aspirates from 30 children with a diagnosis of acute lymphoblastic leukemia were assessed for the expression of messenger RNA for the MDR-1, MRP and LRP genes by semi-quantitative RT-PCR. RESULTS: In the three groups studied, only the increased expression of LRP was related to worsened event-free survival (p = 0.005). The presence of the common acute lymphoblastic leukemia antigen (CALLA) was correlated with increased LRP expression (p = 0.009) and increased risk of relapse or death (p = 0.05). The relative risk of relapse or death was six times higher among children with high LRP expression upon diagnosis (p = 0.05), as confirmed by multivariate analysis of the three genes studied (p = 0.035). DISCUSSION: Cell resistance to drugs is a determinant of the response to chemotherapy and its detection via RT-PCR may be of clinical importance. CONCLUSIONS: Evaluation of the expression of genes for resistance to antineoplastic drugs in childhood acute lymphoblastic leukemia upon diagnosis, and particularly the expression of the LRP gene, may be of clinical relevance, and should be the object of prospective studies.
Downloads
References
Den Boer ML, Pieters R, Kazemier KM, et al. Different expres- sion of glutathione S-transferase alpha, mu and pi in childhood acute lymphoblastic and myeloid leukaemia. Br J Hematol. 1999;104(2):321-7.
Pieters R, Klumper E, Kaspers GJ, et al. Everything you always wanted to know about cellular drug resistance in childhood acute lymphoblastic leukemia. Crit Rev Oncol Hematol. 1997;25(1):11-26.
Brown C. Resistance mechanisms to drugs. In: Brown R, Bo- ger-Brown U, editors. Cytotoxic drug resistance mechanisms. Totowa: Humana Press; 1999. p. 30-59.
Kartner N, Evernden-Porelle D, Bradley G, Ling V. Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies. Nature. 1985;316(6031):820-3
Norgaard JM, Hokland P. Biology of multiple drug resistance in acute leukemia. Int J Hematol. 2000;72(3):290-7.
den Boer ML, Pieters R, Kazemier KM, et al. The modulation effect of PSC 833, cyclosporin A, verapamil and genistein on in vitro cytotoxicity and intracellular content of daunorubi- cin in childhood acute lymphoblastic leukemia. Leukemia. 1998;12(6):912-20.
Szabó D, Keyzer H, Kaiser HE, Molnár J. Reversal of multidrug resistance of tumor cells. Anticancer Res. 2000;20(6B):4261-74.
Brandalise S, Odone V, Pereira W, Andrea M, Zanichelli M, Aranega A. Treatment results of three consecutive Brazilian cooperative childhood ALL protocols: GBTLI-80, GBTLI-82 and -85. ALL Brazilian Group. Leukemia. 1993;7:142-5.
Bennett JM, Catovsky D, Daniel MT, et al.. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51(2):189-99.
Kanerva J, Tiirikainen M, Makipernaa A, et al. Multiple drug resistance mediated by P-glycoprotein is not a major factor in a slow response to therapy in childhood ALL. Pediatr Hematol Oncol. 1998;15(1):11-21.
Kakihara T, Tanaka A, Watanabe A, et al. Expression of multi- drug resistance-related genes does not contribute to risk factors in newly diagnosed childhood acute lymphoblastic leukemia. Pediatr Int. 1999;41(6):641-7.
Dhooge C, De Moerloose B, Laureys G, et al. P-glycoprotein is an independent prognostic factor predicting relapse in childhood acute lymphoblastic leukaemia: results of a 6-year prospective study. Br J Haematol. 1999;105(3):676-83.
Ogretmen B, Barredo JC, Safa AR. Increased expression of lung resistance-related protein and multidrug resistance-associated protein messenger RNA in childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2000;22(1):45-9.
Wuchter C, Leonid K, Ruppert V, et al. Clinical significance of P-glycoprotein expression and function for response to induction hemotherapy, relapse rate and overall survival in acute leukemia. Haematologica. 2000;85(7):711-21.
Sauerbrey A, Voigt A, Wittig S, Hafer R, Zintl F. Messenger RNA analysis of the multidrug resistance related protein (MRP1) and the lung resistance protein (LRP) in de novo and relapsed childhood acute lymphoblastic leukemia. Leuk Lymphoma. 2002;43(4):875-9.
Plasschaert SL, Vellenga E, de Bont ES, et al. High functional P-glycoprotein activity is more often present in T-cell acute lymphoblastic leukaemic cells in adults than in children. Leuk Lymphoma. 2003;44(1):85-95.
Yague E, Armesilla AL, Harrison G, et al. P-glycoprotein (MDR1) expression in leukemic cells is regulated at two distinct steps, mRNA stabilization and translational initiation. J Biol Chem. 2003;278(12):10344-52.
Illmer T, Schuler US, Thiede C, et al. MDR1 gene polymor- phisms affect therapy outcome in acute myeloid leukemia patients. Cancer Res. 2002;62(17):4955-62.
Gupta M, Kumar A, Dabadghao S. Resistance of bcr-abl-positive acute lymphoblastic leukemia to daunorubicin is not mediated by mdr1 gene expression. Am J Hematol. 2002;71(3):172-6.
Brisco MJ, Sykes PJ, Dolman G, et al. Early resistance to therapy during induction in childhood acute lymphoblastic leukemia. Cancer Res. 2000;60(18):5092-6.
